Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
After intravenous administration, proteolytic cleavage in the tumour microenvironment activates the pegulicianine fluorophore. The activated fluorophore emits near-infrared fluorescence when illuminated, enabling intraoperative visualisation of residual cancerous tissue in the lumpectomy cavity.
Indications / reported uses
Adjunct fluorescence imaging in adults with breast cancer to assist intraoperative detection of cancerous tissue within the resection cavity after removal of the primary specimen during lumpectomy surgery; used with an approved fluorescence imaging system.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Pegulicianine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Pegulicianine Permitted Daily Exposure (PDE) report (the Pegulicianine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Pegulicianine Occupational Exposure Limit (OEL) report (the Pegulicianine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.